IMAGE: Dr. Kate Willett, senior author of the report, describes the need for a paradigm shift towards human-relevant research methods. view more
Credit: Troy Seidle HSI
Washington DC (June 7, 2018) – The average pre-approval cost of research and development for a successful drug is estimated to be US$2.6 billion and the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950. More than 90% of drug candidates entering clinical trials fail to gain regulatory approval, mainly as a result of insufficient efficacy and/or unacceptable toxicity, because of the limited predictive value of preclinical, animal-based studies. Without significant intervention, the pipeline responsible for new drug production is predicted to dry up completely within 50 years.
However, great advances have been made in life science technologies and computer science, increasing our ability to generate and analyze data, and there is a growing recognition that, to improve the success rate, a stronger focus on human-relevant data is needed. Proceedings of a multistakeholder workshop co-organized by The Humane Society of the United States, Humane Society International and the National Institutes of Health under the auspices of the global BioMed21 Collaboration (biomed21.org) is published in
Article originally posted at